Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

The Timing of Hip Arthroscopy After Intra‐articular Hip Injection Affects Postoperative Infection Risk
Coleman, Struan H. , Kelly, Bryan T. , Werner, Brian C. , Wang, Dean , Camp, Christopher L. , Ranawat, Anil S.

Mayo Clinic

Arthroscopy | August 8, 2017 | Volume: 33 | Issue: 11 | Pages: 1988

10.1016/j.arthro.2017.06.037 | PMID 28800918 Get It

Purpose To evaluate the association of preoperative intra‐articular hip injection with surgical site infection after hip arthroscopy. Methods A large administrative database was used to identify all patients undergoing hip arthroscopy from 2007 to 2015 within a single private insurer and from 2005 to 2012 within Medicare in the United States. Those that received an ipsilateral preoperative intra‐articular hip injection were identified. The patients were then divided into the following groups based on the interval between preoperative injection and ipsilateral hip arthroscopy: (1) <3 months, (2) 3 to 6 months, and (3) 6 to 12 months. These groups were compared to a control group composed of patients with no history or a remote history (>12 months) of preoperative hip injection. Patients developing a surgical site infection within 6 months following hip arthroscopy were identified using International Classification of Diseases, Ninth Revision, and Current Procedural Terminology codes associated with infection. Groups were compared using a multivariate logistic regression analysis to control for age, gender, body mass index, smoking status, alcohol usage, and multiple medical comorbidities including diabetes mellitus, hemodialysis use, inflammatory arthritis, and peripheral vascular disease. Results In total, 19% of privately insured and 6% of Medicare patients received a hip injection within 12 months of hip arthroscopy. The overall infection rate in privately insured and Medicare patients was 1.19% and 1.10%, respectively. Preoperative hip injection within 3 months of surgery was associated with a significantly higher risk of postoperative infection versus controls (2.16%, odds ratio [OR] 6.1, P < .001, for privately insured group; 2.80%, OR 1.99, P = .037, for Medicare group). In contrast, preoperative hip injection given after more than 3 months of surgery was not associated with an increased risk of postoperative infection versus controls. Conclusions Risk of infection after hip arthroscopy increased when preoperative intra‐articular hip injections were given within 3 months of surgery. Level of Evidence Level III, retrospective comparative study.
Submillimeter alignment of more than three contiguous vertebrae in spinal SRS/SBRT with 6‐degree couch
Luo, Dershan , Yang, James N., Yang, Jinzhong , Chang, Eric L. , Brown, Paul D. , McAleer, Mary Frances , Ghia, Amol J. , Wang, Xin , Zhao, Zhongxiang , Li, Jing , Yang, Jinzhong

Mayo Clinic

Journal of Applied Clinical Medical Physics | August 8, 2017 | Volume: 18 | Issue: 5 | Pages: 225-236

10.1002/acm2.12153 | PMID 28786235 Get It

AbstractThe purpose of this study is to identify regions of spinal column in which more than three contiguous vertebrae can be reliably and quickly aligned within 1 mm using a 6‐degree (6D) couch and full body immobilization device. We analyzed 45 cases treated over a 3‐month period. Each case was aligned using ExacTrac x‐ray positioning system with integrated 6D couch to be within 1° and 1 mm in all six dimensions. Cone‐Beam computed tomography (CBCT) with at least 17.5 cm field of view (FOV) in the superior–inferior direction was taken immediately after ExacTrac positioning. It was used to examine the residual error of five to nine contiguous vertebrae visible in the FOV. The residual error of each vertebra was determined by expanding/contracting the vertebrae contour with a margin in millimeter integrals on the planning CT such that the new contours would enclose the corresponding vertebrae contour on CBCT. Submillimeter initial setup accuracy was consistently achieved in 98% (40/41) cases for a span of five or more vertebrae starting from T2 vertebra and extending caudally to S5. The curvature of spinal column along the cervical region and cervicothoracic junction was not easily reproducible between treatment and simulation. Fifty‐seven percent (8/14) of cases in this region had residual setup error of more than 1 mm in nearby vertebrae after alignment using 6D couch with image guidance. In conclusion, 6D couch integrated with image guidance is convenient and accurately corrects small rotational shifts. Consequently, more than three contiguous vertebrae can be aligned within 1 mm with immobilization that reliably reproduces the curvature of the thoracic and lumbar spinal column. Ability of accurate setup is becoming less a concern in limiting the use of stereotactic radiosurgery or stereotactic body radiation therapy to treat multilevel spinal target.
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
Alberts, Rudi , Vries, Elisabeth M. G. de, Goode, Elizabeth C. , Jiang, Xiaojun , Sampaziotis, Fotis , Rombouts, Krista , Böttcher, Katrin , Folseraas, Trine , Weismüller, Tobias J. , Alexander, Graeme, Alvaro, Domenico , Bergquist, Annika , Björkström, Niklas K. , Beuers, Ulrich , Boberg, Kirsten Muri , Bowlus, Christopher L. , Bragazzi, Maria Consiglia , Chazouillères, Olivier , Cheung, Angela , Dalekos, Georgios, Eaton, John E. , Eksteen, Bertus , Ellinghaus, David , Färkkilâ, Martti , Festen, Eleonora A. , Floreani, Annarosa , Franceschet, I., Gotthardt, Daniel , Hoek, Bart van , Holm, Kristian , Hov, Johannes R. , Imhann, Floris , Juran, Brian D., Lenzen, Henrike , Marschall, Hanns–Ulrich , Marzioni, Marco , Melum, Espen , Milkiewicz, Piotr , Müller, Tobias , Parés, Albert , Rupp, Christian , Rust, Christian, Sandford, Richard , Schrumpf, Erik, Silverberg, Mark S. , Srivastava, Brijesh, Sterneck, Martina , Teufel, Andreas , Vallier, Ludovic , Verheij, Joanne , Vila, Arnau Vich , Vries, Boudewijn de, Zachou, Kalliopi , Chapman, Roger W. , Manns, Michael P. , Rushbrook, Simon, Anderson, Carl A. , Karlsen, Tom H. , Ponsioen, Cyriel Y. , Weersma, Rinse K. , Eaton, John, Lazaridis, Konstantinos N. , Ellinghaus, David , Bowlus, Christopher L , Marzioni, Marco , Mason, Andrew L. , Wang, Weiwei , Bjornsson, Einar Stefan , Carbone, Marco , Dalekos, Georgios, Hirschfield, Gideon M. , Hohenester, Simon D. , Invernizzi, Pietro , Lieb, Wolfgang , Liu, Jimmy Z. , Schramm, Christoph , Schreiber, Stefan , Pinzani, Massimo , Franke, André , Bergquist, Annika , Milkiewicz, Piotr , Alvaro, Domenico , Hov, Johannes R , Anderson, Carl A

Mayo Clinic

Gut | August 4, 2017 | Volume: 67 | Issue: 8 | Pages: 1517-1524

10.1136/gutjnl-2016-313598 | PMID 28779025 Get It

Objective Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications. Design We collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportional hazards models, we identified genetic variants associated with binary and time-to-event PSC subphenotypes. Results We identified genetic variant rs853974 to be associated with liver transplant-free survival (p=6.07×10–9). Kaplan-Meier survival analysis showed a 50.9% (95% CI 41.5% to 59.5%) transplant-free survival for homozygous AA allele carriers of rs853974 compared with 72.8% (95% CI 69.6% to 75.7%) for GG carriers at 10 years after PSC diagnosis. For the candidate gene in the region, RSPO3, we demonstrated expression in key liver-resident effector cells, such as human and murine cholangiocytes and human hepatic stellate cells. Conclusion We present a large international PSC cohort, and report genetic loci associated with PSC disease progression. For liver transplant-free survival, we identified a genome-wide significant signal and demonstrated expression of the candidate gene RSPO3 in key liver-resident effector cells. This warrants further assessments of the role of this potential key PSC modifier gene.
Basolateral delivery of the type I transforming growth factor beta receptor is mediated by a dominant-acting cytoplasmic motif
Yin, Xueqian , Kang, Jeong Han , Andrianifahanana, Mahefatiana, Jung, Mi-Yeon, Hernandez, Danielle M. , Leof, Edward B. , Wang, Youli

Mayo Clinic

Molecular Biology of the Cell | August 3, 2017 | Volume: 28 | Issue: 20 | Pages: 2701-2711

10.1091/mbc.e17-05-0334 | PMID 28768825 Get It

Delivery of biomolecules to the correct subcellular locales is critical for proper physiological function. To that end, we have previously determined that type I and II transforming growth factor beta (TGF-β) receptors (TβRI and TβRII, respectively) localize to the basolateral domain in polarized epithelia. While TβRII targeting was shown to be regulated by sequences between amino acids 529 and 538, the analogous region(s) within TβRI is unknown. To address that question, sequential cytoplasmic TβRI truncations and point mutations identified a targeting motif between residues 158 and 163 (VxxEED) required for basolateral TβRI expression. Further studies documented that receptor internalization, down-regulation, direct recycling, or Smad signaling were unaffected by motif mutations that caused TβRI mislocalization. However, inclusion of amino acids 148–217 containing the targeting motif was able to direct basolateral expression of the apically sorted nerve growth factor receptor (NGFR, p75; extracellular and transmembrane regions) in a dominant manner. Finally, coexpression of apically targeted type I and type II TGF-β receptors mediated Smad3 signaling from the apical membrane of polarized epithelial cells. These findings demonstrate that the absence of apical TGF-β signaling in normal epithelia is primarily a reflection of domain-specific receptor expression and not an inability to couple with the signaling machinery.
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasiv
Hendry, Shona , Salgado, Roberto , Gevaert, Thomas, Russell, Prudence A. , John, Tom, Thapa, Bibhusal , Estrada, Mónica V. , González-Ericsson, Paula I. , Solomon, Benjamin , Solinas, Cinzia , Eynden, Gert G. G. M. Van den, Preusser, Matthias , Hainfellner, Johannes A. , Pruneri, Giancarlo , Vingiani, Andrea , Demaria, Sandra , Symmans, Fraser, Nucíforo, Paolo , Comerma, Laura , Thompson, E. Aubrey , Kim, Seong-Rim , Schnitt, Stuart J. , Colpaert, Cécile , Scherer, Stefan, Viale, Giuseppe , Sirtaine, Nicolas , Penault‐Llorca, Frédérique, Sugie, Tomohagu, Fineberg, Susan , Paik, Soonmyung , Richardson, Andrea L., Wang, Yihong , Chmielik, Ewa , Brock, Jane B. , Johnson, Douglas B. , Wienert, Stephan, Bossuyt, Veerle , Michiels, Stefan , Ternès, Nils, Burchardi, Nicole, Klauschen, Frederick , Watson, Peter H. , Nelson, Brad H. , O’Toole, Sandra A., Larsimont, Denis , Wind, Roland de, Curigliano, Giuseppe , André, Fabrice , Vijver, Marc J. van de , Rojo, Federico , Floris, Giuseppe , Bedri, Shahinaz , Sparano, Joseph A. , Rimm, David L. , Kos, Zuzana , Hewitt, Stephen M. , Farshid, Gelareh , Loibl, Sibylle , Allison, Kimberly H. , Adams, Sylvia , Willard‐Gallo, Karen , Gandhi, Leena , Moreira, André L. , Hirsch, Fred R. , Dieci, Maria Vittoria , Urbanowicz, María, Brčić, Iva , Korski, Konstanty, Gaire, Fabien, Koeppen, Hartmut , Lo, Amy, Rebelatto, Marlon C., Steele, Keith E. , Zha, Jiping, Emancipator, Kenneth , Juco, Jonathan, Loi, Sherene , Fox, Stephen B. , Symmans, W. Fraser , John, Thomas , Wang, Yihong , Gonzalez-Ericsson, Paula I , Curigliano, Giuseppe , Sparano, Joseph A , Nelson, Brad H , Preusser, Matthias , André, Fabrice , Symmans, W Fraser , Loi, Sherene , John, Tom, Christie, Michael , Van de Vijver, Koen , Sanders, Melinda E. , Allory, Yves , Lakhani, Sunil R. , Sotiriou, Christos P. , Ignatiadis, Michail , Badve, Sunil , Pierce, Robert Hamilton , Srinivasan, Ashok , Richardson, Andrea L. , Balko, Justin M. , Luen, Stephen James , Savas, Peter Stephen , Criscitiello, Carmen , Lacroix‐Triki, Magali , Nielsen, Torsten O. , Singh, Baljit , Tung, Nadine , Horlings, Hugo , Lo, Amy, Giltnane, Jennifer Margaret , Denkert, Carsten , Reis‐Filho, Jorge S. , Pruneri, Giancarlo , Rimm, David , Dieci, Maria Vittoria , Nuciforo, Paolo , Solomon, Benjamin J

Mayo Clinic

Advances in Anatomic Pathology | August 2, 2017 | Volume: 24 | Issue: 5 | Pages: 235-251

10.1097/pap.0000000000000162 | PMID 28777142 Get It

Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinoma
Hendry, Shona , Salgado, Roberto , Gevaert, Thomas, Russell, Prudence A. , John, Tom, Thapa, Bibhusal , Estrada, Mónica V. , González-Ericsson, Paula I. , Sanders, Melinda, Solomon, Benjamin , Solinas, Cinzia , Eynden, Gert G. G. M. Van den, Preusser, Matthias , Hainfellner, Johannes A. , Pruneri, Giancarlo , Vingiani, Andrea , Demaria, Sandra , Symmans, Fraser, Nucíforo, Paolo , Comerma, Laura , Thompson, E. Aubrey , Kim, Seong-Rim , Schnitt, Stuart J. , Colpaert, Cécile , Scherer, Stefan, Viale, Giuseppe , Sirtaine, Nicolas , Sugie, Tomohagu, Fineberg, Susan , Paik, Soonmyung , Richardson, Andrea L., Wang, Yihong , Chmielik, Ewa , Brock, Jane, Johnson, Douglas B. , Wienert, Stephan, Bossuyt, Veerle , Michiels, Stefan , Ternès, Nils, Burchardi, Nicole, Savas, Peter, Klauschen, Frederick , Watson, Peter H. , Nelson, Brad H. , O’Toole, Sandra A., Larsimont, Denis , Wind, Roland de, Curigliano, Giuseppe , André, Fabrice , Vijver, Marc J. van de , Rojo, Federico , Floris, Giuseppe , Bedri, Shahinaz , Sparano, Joseph A. , Rimm, David L. , Kos, Zuzana , Hewitt, Stephen M. , Farshid, Gelareh , Loibl, Sibylle , Allison, Kimberly H. , Adams, Sylvia , Willard‐Gallo, Karen , Gandhi, Leena , Hirsch, Fred R. , Dieci, Maria Vittoria , Urbanowicz, María, Brčić, Iva , Korski, Konstanty, Gaire, Fabien, Koeppen, Hartmut , Lo, Amy, Rebelatto, Marlon C., Steele, Keith E. , Zha, Jiping, Emancipator, Kenneth , Juco, Jonathan, Loi, Sherene , Fox, Stephen B. , Symmans, W. Fraser , John, Thomas , Wang, Yihong , Gonzalez-Ericsson, Paula I , Curigliano, Giuseppe , Sparano, Joseph A , Nelson, Brad H , Preusser, Matthias , André, Fabrice , Symmans, W Fraser , Loi, Sherene , John, Tom, Christie, Michael , Van de Vijver, Koen , Allory, Yves , Lakhani, Sunil R. , Sotiriou, Christos P. , Ignatiadis, Michail , Badve, Sunil , Pierce, Robert Hamilton , Penault-Llorca, Frederique Madeleine , Srinivasan, Ashok , Richardson, Andrea L. , Balko, Justin M. , Luen, Stephen James , Savas, Peter Stephen , Criscitiello, Carmen , Lacroix‐Triki, Magali , Nielsen, Torsten O. , Singh, Baljit , Tung, Nadine , Horlings, Hugo , Moreira, Andre M. , Lo, Amy, Giltnane, Jennifer Margaret , Denkert, Carsten , Reis‐Filho, Jorge S. , Pruneri, Giancarlo , Rimm, David , Dieci, Maria Vittoria , Nuciforo, Paolo , Solomon, Benjamin J

Mayo Clinic

Advances in Anatomic Pathology | August 2, 2017 | Volume: 24 | Issue: 6 | Pages: 311-335

10.1097/pap.0000000000000161 | PMID 28777143 Get It

Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecologic system, and head and neck, as well as primary brain tumors, mesothelioma and melanoma. The particularities and different emphases in TIL assessment in different tumor types are discussed. The standardized methodology we propose can be adapted to different tumor types and may be used as a standard against which other approaches can be compared. Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.
Abstract 766: Comorbidities limiting recruitment of non-small cell lung cancer (NSCLC) patients in early phase trials
Duma, Narjust , Wang, Yucai , Mansfield, Aaron S.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 766-766

10.1158/1538-7445.am2017-766 Get It

Abstract Background: Early phase trials (EPCT) provide significant value by evaluating the possible benefits of new agents. The eligibility criteria in EPCT are usually rigorous and may exclude many patients (pts) commonly seen in clinical practice. Our objective was to identify the most common comorbidities excluded in EPCT for NSCLC. Methods: ClinicalTrials.gov was queried on August 1st of 2016. 299 interventional drug trials were extracted from 2010 to 2016. We studied the trial characteristics including: experimental therapy, location, funding and eligibility criteria. Exclusion of CNS metastasis was treated as a binary variable (strict exclusion vs. allowed). Logistic regressions were used for statistical analysis. Results: Of the 299 trials, 164 (55%) were phase II, 81 (27%) phase I and 54 (18%) phase Ib/II. 164 (55%) were conducted in the United States (US), 45 (15%) in Asia, 39 (13%) in Europe and 51 (17%) were international. 171 (57%) trials were funded by the industry, 54 (18%) by government agencies and 74 (25%) were investigator initiated. Survival was an end-point in 97 (32%) trials. 70 (23%) trials required a repeat lung biopsy. 54 (18%) trials excluded pts &gt;75 years of age. 99 (33%) trials required creatinine levels &lt;1.5 mg/dl, 132 (44%) liver enzymes &lt;2.5 and total bilirubin &lt;1.5 of the upper limit of normal. 88 (29%) trials required Hgb&gt;9 g/dl and 141 (47%) excluded pts with platelets &lt;100,000/dl. In terms of comorbidities, 84 (28%) trials excluded pts with atrial fibrillation, 94 (31%) with any anticoagulation therapy and 120 (40%) HIV positive pts. CNS involvement was a significant exclusion factor, 123 (41%) trials excluded pts with CNS metastasis. On univariate analysis, the odds of CNS metastasis exclusion were significantly higher in immunotherapy trials (OR 1.72, 95%CI 1.2-2.4, p&lt;0.01) and lower in European trials (OR 0.76, 95%CI 0.6-0.9, p&lt;0.005). In multivariate analysis, US based trials had higher odds of exclusion of CNS metastasis (OR: 3.2, 95%CI 1.4-7.5, p&lt;0.05). Conclusions: Many of the EPCTs excluded pts with advanced age, cytopenias and other common comorbidities, eliminating the possibility of many of our aging pts from participation. Regarding CNS disease, our analysis suggests the type of agent and location may influence the trial design about CNS metastasis inclusion. Investigators should review whether sufficient justification exists for every exclusion criterion before their incorporation in future trial protocols. Citation Format: Narjust Duma, Yucai Wang, Aaron Mansfield. Comorbidities limiting recruitment of non-small cell lung cancer (NSCLC) patients in early phase trials [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 766. doi:10.1158/1538-7445.AM2017-766
Abstract LB-274: Whole-exome sequencing reveals tyrosine kinase-resistant mutations in pretreatment EGFR-mutant lung adenocarcinomas
Gao, Xuyuan , Xu, Hang , Chan, Oscar SH, Xu, Feng , Wang, Junwen , Tin, Vicky Pc, Xiao, Zhijie , Wang, Siqi , Wong, Maria Pik , Wang, Junwen , Ho, Jcm , Lee, Victor , Yam, Judy Wai Ping

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: LB-274-LB-274

10.1158/1538-7445.am2017-lb-274 Get It

Abstract Lung cancer is the most lethal malignancy around the world. In Hong Kong, chronic tobacco use is prevalent in male but &lt;20% of female patients smoke. Epidermal growth factor receptor (EGFR) mutations affect 30% and 67% of male and female lung adenocarcinomas, respectively. Treatment responses to tyrosine kinase inhibitors (TKI) are not uniform and all patients eventually develop drug resistance. Mutation screening of immediate pre-treatment tumors is the most ideal for assessing drug targets but in practice, excision specimens of primary or metastatic sites are more efficient in terms of tumor quantity, timeliness and patient acceptance. However, information on the applicability of this approach and correlation with the clinical outcome is limited. For this purpose, we compared the whole exome mutation profiles of 39 excised EGFR mutant cancers treated with first line TKI with the clinical response type, including 15 stage I/II and 24 stage III/IV tumors. They included 16 non-responders (NR) defined clinically as those with stable or progressive disease, and 23 responders (R) defined by partial or complete tumor shrinkage. Considering only the non-synonymous SNV and INDEL mutations of coding regions of known actionable targets and genes listed in both the CGC and COSMIC cancer databases, the tumors harbored 54 mutated genes including 26 recurrently mutated and 28 genes involving only 1 tumor. Excluding EGFR, TP53 was the most commonly mutated gene occurring in 25/39 (64.1%) cases. Most known resistant genes involved in the EGFR and bypass signaling network showed mutations only in the NR group including recurrent mutations of PTEN (3/16), PIK3CA (2/16) and NF1 (2/16), and single case mutations of AKT1, ALK, RAF1 and KDR. Two EGFR network candidates showed mutations in both the NR and R groups, including HGF (2/16 NR, 1/23 R) and ROS1 (1 case in either group). Four post-treatment (post-TKI) tumors of acquired resistance were also analyzed, all of which showed EGFR T790M while no pre-treatment NR or R tumor harbored this mutation. Notably, mutations in the β-catenin pathway were prominent in the NR and post-TKI tumors, including APC (2/16 NR), CTNNB1 (1/16 NR, 1/4 post-TKI) and c-MYC (1/16 NR, 1/4 post-TKI) while they were not detected in the R tumors. Also, nonsense mutations of ARID1A was observed in 2/16 NR but none of the R tumors. In summary, our findings revealed candidate TKI resistant mutations involving the EGFR and bypass signaling networks in pre-treatment excision specimens particularly in non-responding patients. The EGFR T790M was not detectable in pre-treatment samples but was prevalent in post-TKI treated cancers. While this study is limited by its small cohort size, the findings indicate deep sequencing analysis of pre-treatment excision specimens of EGFR-mutant lung adenocarcinomas is warranted for detection of resistant mutations and predicting treatment response. Note: This abstract was not presented at the meeting. Citation Format: Xu-yuan Gao, Hang Xu, James CM Ho, Oscar SH Chan, Feng Xu, Junwen Wang, Victor HF Lee, Vicky PC Tin, Zhijie Xiao, Siqi Wang, Judy WP Yam, Maria P. Wong. Whole-exome sequencing reveals tyrosine kinase-resistant mutations in pretreatment EGFR-mutant lung adenocarcinomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-274. doi:10.1158/1538-7445.AM2017-LB-274
Abstract 4313: Protein synthesis modulates paraptotic death induced by inhibition of cyclophilins in glioblastoma (GBM) cells
Bram, Richard J. , Wang, Lin , Gundelach, Justin H.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 4313-4313

10.1158/1538-7445.am2017-4313 Get It

Abstract In this study, we investigated the mechanisms underlying cell death induced by the small molecule cyclophilin inhibitor NIM811. NIM811 effectively killed GBM cells through a non-apoptotic pathway, as there was no nuclear shrinkage or caspase activation. Instead, death was preceded by dramatic cytosolic vacuolization, stemming from enlargement of the endoplasmic reticulum (ER). RNA-seq revealed upregulation of genes pertinent to the unfolded protein response (UPR) and autophagy. Western blotting for UPR and autophagy mediators also supported a transient UPR signaling and compromised autophagy during prolonged NIM811 treatment. By utilizing a bicistronic reporter plasmid, we independently quantitated Cap-dependent and Cap-independent translation. We further assessed the long-term effects mediated by different short-term paraptosis inhibitors via colony formation assay. We find that NIM811 initiates paraptosis in GBM cells, due to an abnormal upregulation of protein translation that caused accumulation of misfolded or unfolded proteins in ER. Transient activation of pro-survival autophagy and UPR signals were shutdown during prolonged treatment with NIM811, thus allowing cell death to occur. Cycloheximide was previously reported by others to suppress paraptosis. In our studies, we find instead that it temporarily delayed vacuole formation, but actually enhanced paraptotic cell death in the long term. The mTOR inhibitors rapamycin or torin-2 rescued cells from NIM811 induced paraptosis by sustaining autophagy and the UPR, and specifically restrained cap-dependent translation. We propose that ER vacuolization could be a protective response generated by cells to isolate defective proteins within the ER in order to prevent misfolded aggregates to interfere with cellular homeostasis. For that reason, simply inhibiting vacuole formation without clearing protein accumulation in the ER was insufficient to prevent cell death. These findings aid our understanding of cellular mechanisms that contribute to non-apopotic death. Moreover, this work underlines the importance of evaluating cellular responses in cell death experiments over multiple time frames to judge the true impact. Citation Format: Lin Wang, Justin Gundelach, Richard Bram. Protein synthesis modulates paraptotic death induced by inhibition of cyclophilins in glioblastoma (GBM) cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4313. doi:10.1158/1538-7445.AM2017-4313
Abstract 425: SMRT® Sequencing of full-length androgen receptor isoforms in prostate cancer reveals previously hidden drug resistant variants
Ho, Yeung, Etten, Jamie L. Van, Li, Yingming , Tseng, Elizabeth , Hon, Ting, Silverstein, Kevin A.T. , Wang, Liewei , Kohli, Manish , Hillman, David W. , Henzler, Christine M. , Yang, Rendong , Clark, Tyson A. , Wang, Liguo , Dehm, Scott M.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 425-425

10.1158/1538-7445.am2017-425 Get It

Abstract Prostate cancer is the most frequently diagnosed male cancer. For prostate cancer that has progressed to an advanced or metastatic stage, androgen deprivation therapy (ADT) is the standard of care. ADT inhibits activity of the androgen receptor (AR), a master regulator transcription factor in normal and cancerous prostate cells. The major limitation of ADT is the development of castration-resistant prostate cancer (CRPC), which is almost invariably due to transcriptional re-activation of the AR. One mechanism of AR transcriptional re-activation is expression of AR-V7, a truncated, constitutively active AR variant (AR-V) arising from alternative AR pre-mRNA splicing. Noteworthy, AR-V7 is being developed as a predictive biomarker of primary resistance to androgen receptor (AR)-targeted therapies in CRPC. Multiple additional AR-V species are expressed in clinical CRPC, but the extent to which these may be co-expressed with AR-V7 or predict resistance is not known. Here we utilized long read sequencing to identify and quantify AR isoforms expressed in CRPC. To unambiguously characterize all AR isoforms, we prepared Iso-Seq™ libraries via 3’ rapid amplification of cDNA ends (RACE) with RNA isolated from prostate cancer cell lines and xenograft tissues using a forward primer anchored in AR exon 1. 3’RACE reactions were subjected to single molecule, real-time (SMRT®) long-read sequencing with a Pacific Biosciences RSII System. Our work identified AR-V9 as a truncated isoform that is frequently co-expressed with AR-V7 in CRPC. Mechanistically, our work re-annotated AR-V7 and AR-V9 mRNAs, showing these two species shared a common 3’ terminal exon containing separate splice acceptor sites. Taking into account this new information, novel siRNAs and antibodies which could distinguish between AR-V7 and AR-V9 were designed, validated and used to measure the relative expression of these two AR isoforms in CRPC cells with a view to determining the potential of AR-V9 as a predictive biomarker of primary resistance to AR-targeted therapies. Citation Format: Manish Kohli, Yeung Ho, David W. Hillman, Jamie L. Van Etten, Christine Henzler, Rendong Yang, Yingming Li, Elizabeth Tseng, Ting Hon, Tyson A. Clark, Liguo Wang, Kevin Silverstein, Liewei Wang, Scott M. Dehm. SMRT® Sequencing of full-length androgen receptor isoforms in prostate cancer reveals previously hidden drug resistant variants [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 425. doi:10.1158/1538-7445.AM2017-425